| Literature DB >> 33109449 |
Khaled M Elsayes1, Robert M Marks2, Serageldin Kamel3, Alexander J Towbin4, Ania Z Kielar5, Parth Patel6, Victoria Chernyak7, Kathryn J Fowler8, Sameh Nassar9, Moataz A Soliman10, Aya Kamaya11, Mishal Mendiratta-Lala12, Amir A Borhani10, David T Fetzer13, Alice W Fung14, Richard K G Do15, Mustafa R Bashir16, James Lee17, Nikita Consul18, Richard Olmsted18, Avinash Kambadakone19, Bachir Taouli20, Alessandro Furlan21, Claude B Sirlin8, Peggy Hsieh22.
Abstract
PURPOSE: The SARS-CoV-2 pandemic has drastically disrupted radiology in-person education. The purpose of this study was to assess the implementation of a virtual teaching method using available technology and its role in the continuity of education of practicing radiologists and trainees during the pandemic.Entities:
Keywords: COVID-19; e-learning; education; liver imaging; pandemic; radiologists; residency; teaching; virtual learning
Mesh:
Year: 2020 PMID: 33109449 PMCID: PMC7538097 DOI: 10.1016/j.acra.2020.10.001
Source DB: PubMed Journal: Acad Radiol ISSN: 1076-6332 Impact factor: 3.173
Course Topics, Speakers, and Participants/Webinar
| Session # | Date | Topic(s) | Max Participants |
|---|---|---|---|
| 1 | 20-Apr | What's LI-RADS? History & Evolution | 343 |
| 2 | 21-Apr | LI-RADS: Overview of CT/MR algorithm and major features | 279 |
| 3 | 22-Apr | Malignant lesions that are not definitely HCC: LR-M | 274 |
| 4 | 23-Apr | LI-RADS: Tumor in Vein | 167 |
| 5 | 24-Apr | LI-RADS Ancillary features | 142 |
| 6 | 27-Apr | Pitfalls in Cirrhosis Imaging and User Errors in applying LI-RADS | 151 |
| 7 | 28-Apr | LI-RADS: HCC Treatment Response: from Concepts to Algorithms | 89 |
| 8 | 30-Apr | Present and Future of LI-RADS | 50 |
| 9 | 1-May | LI-RADS Case-based Review | 60 |
| 10 | 4-May | LI-RADS: Is There a Clinical Need? | 57 |
| 11 | 5-May | Management Implications of LI-RADS Categories | 57 |
| 12 | 6-May | LI-RADS Technical Recommendation | 45 |
| 13 | 7-May | Ultrasound Screening of Hepatocellular Carcinoma | 46 |
| 14 | 8-May | Contrast Enhanced Ultrasound of the Liver | 42 |
| 15 | 11-May | Imaging of Liver Iron Deposition and Steatosis | 71 |
| 16 | 12-May | Abbreviated MRI for HCC surveillance | 59 |
| 17 | 13-May | Liver MR Technique Related Pitfalls | 50 |
| 18 | 14-May | MR Imaging of Hepatic Adenomas: Subtypes and their Management | 48 |
| 19 | 15-May | Hepatocellular Carcinoma: LI-RADS Treatment Response after locoregional therapy | 43 |
| 20 | 18-May | Liver Directed Therapy for HCC | 39 |
| 21 | 19-May | Y90 Microspheres: State of the Science | 37 |
| 22 | 20-May | Cholangiocarcinoma: Current concepts | 42 |
| 23 | 21-May | Assessment of Pediatric Liver Tumors | 85 |
| 24 | 22-May | Liver malignancy masquerading as benignancy and how LI-RADS fits in | 38 |
| 25 | 26-May | Imaging Evaluation of Liver Transplantation | 51 |
| 26 | 27-May | Liver Transplantation: What Surgeons Expect from Radiologists | 38 |
| 27 | 28-May | The globalization of LI-RADS: roadmap and barriers to overcome | 31 |
| 28 | 29-May | Hepatocarcinogenesis: Rad./Path Correlation | 49 |
YouTube Views Per Video (As of July 9, 2020)
| Video Title | Video Publish Time | Views |
|---|---|---|
| 1. What's LI-RADS? History & Evolution - Part 1. | 4/21/2020 | 2367 |
| 2. What's LI-RADS? History & Evolution - Part 2 | 4/21/2020 | 1260 |
| 3. LI-RADS: Overview of CT/MR algorithm and major features - Part 1 | 4/22/2020 | 1734 |
| 4. LI-RADS: Overview of CT/MR algorithm and major features - Part 2 | 4/22/2020 | 828 |
| 5. LI-RADS: Malignant lesions that are not definitely HCC: LR-M - Part 1 | 4/23/2020 | 1110 |
| 6. LI-RADS: Malignant lesions that are not definitely HCC: LR-M - Part 2 | 4/23/2020 | 558 |
| 7. LI-RADS; LR- Tumor In Vein (TIV) - Part 1 | 4/24/2020 | 709 |
| 8. LI-RADS; LR- Tumor In Vein (TIV) - Part 2 (Q&A). | 4/24/2020 | 461 |
| 9. LI-RADS Ancillary Features - Part 1. | 4/25/2020 | 695 |
| 10. LI-RADS Ancillary Features - Part 2 | 4/26/2020 | 369 |
| 11. Pitfalls in Cirrhosis Imaging and User Errors in applying LI-RADS - Part 1. | 4/28/2020 | 1631 |
| 12. Pitfalls in Cirrhosis Imaging and User Errors in applying LI-RADS - Part 2. | 4/28/2020 | 464 |
| 13. LI-RADS: HCC Treatment Response: from Concepts to Algorithms - Part 1. | 4/29/2020 | 537 |
| 14. LI-RADS: HCC Treatment Response: from Concepts to Algorithms - Part 2 | 4/29/2020 | 311 |
| 15. Present and Future of LI-RADS - Part 1. | 5/1/2020 | 326 |
| 16. Present and Future of LI-RADS - Part 2 (Q&A). | 5/1/2020 | 161 |
| 17. LI-RADS Case-based Review - Part 1. | 5/2/2020 | 625 |
| 18. LI-RADS Case-based Review - Part 2 (Q&A). | 5/2/2020 | 293 |
| 19. LI-RADS: Is There a Clinical Need? - Part 1. | 5/5/2020 | 273 |
| 20. LI-RADS: Is There a Clinical Need? - Part 2 (Q&A). | 5/5/2020 | 128 |
| 21. Management Implications of LI-RADS Categories - Part 1. | 5/6/2020 | 285 |
| 22. Management Implications of LI-RADS Categories - Part 2 | 5/6/2020 | 189 |
| 23. Ultrasound Screening of Hepatocellular Carcinoma - Part 1. | 5/7/2020 | 305 |
| 24. Ultrasound Screening of Hepatocellular Carcinoma - Part 2 (Q&A). | 5/7/2020 | 173 |
| 25. LI-RADS Technical Recommendation - Part 1. | 5/8/2020 | 288 |
| 26. LI-RADS Technical Recommendation - Part 2 (Q&A). | 5/8/2020 | 123 |
| 27. Contrast Enhanced Ultrasound of the Liver - Part 1. | 5/9/2020 | 266 |
| 28. Contrast Enhanced Ultrasound of the Liver - Part 2 | 5/9/2020 | 78 |
| 29. Imaging of Liver Iron Deposition and Steatosis - Part 1. | 5/12/2020 | 348 |
| 30. Imaging of Liver Iron Deposition and Steatosis - Part 2 | 5/12/2020 | 124 |
| 31. Abbreviated MRI for HCC surveillance - Part 1. | 5/13/2020 | 171 |
| 32. Abbreviated MRI for HCC surveillance - Part 2 | 5/13/2020 | 75 |
| 33. Liver MR Technique Related Pitfalls. | 5/14/2020 | 235 |
| 34. MR Imaging of Hepatic Adenomas: Subtypes and Their Management - Part 1. | 5/15/2020 | 365 |
| 35. MR Imaging of Hepatic Adenomas: Subtypes and Their Management - Part 2 | 5/15/2020 | 137 |
| 3. Virology and Immunology of COVID-19. | 5/17/2020 | 163 |
| 36. Hepatocellular Carcinoma: LI-RADS Treatment Response after locoregional therapy - Part 1 | 5/18/2020 | 302 |
| 37. Hepatocellular Carcinoma: LI-RADS Treatment Response after locoregional therapy - Part 2 (Q&A) | 5/18/2020 | 123 |
| 38. Liver Directed Therapy for HCC - Part 1 | 5/19/2020 | 175 |
| 39. Liver Directed Therapy for HCC - Part 2 | 5/19/2020 | 70 |
| 40. Y90 Microspheres: State of the Science - Part 1. | 5/19/2020 | 160 |
| 41. Y90 Microspheres: State of the Science - Part 2. | 5/19/2020 | 54 |
| 42. Cholangiocarcinoma: Current concepts - Part 1. | 5/20/2020 | 368 |
| 43. Cholangiocarcinoma: Current concepts - Part 2(Q&A). | 5/20/2020 | 143 |
| 44. Assessment of Pediatric Liver Tumors - Part 1 . | 5/21/2020 | 281 |
| 45. Assessment of Pediatric Liver Tumors - Part 2(Q&A) . | 5/21/2020 | 72 |
| 46. Liver malignancy masquerading as benignancy and how LI-RADS fits in-Part 1. | 5/22/2020 | 270 |
| 47.Liver malignancy masquerading as benignancy... - Part 2(Q&A) . | 5/22/2020 | 120 |
| 48. Imaging Evaluation of Liver Transplantation Part 1. | 5/26/2020 | 272 |
| 49. Imaging Evaluation of Liver Transplantation Part 2(Q&A). | 5/26/2020 | 136 |
| 50. Liver Transplantation; (What Surgeons Expect from Radiologists). Part 1. | 5/29/2020 | 192 |
| 51.Liver Transplantation; What Surgeons Expect from Radiologists. part2(Q&A). | 5/29/2020 | 136 |
| 52. The globalization of LI-RADS: roadmap and barriers to overcome. | 5/29/2020 | 107 |
| 53.Hepatocarcinogenesis; Rad./Path Correlation. | 6/12/2020 | 221 |
| Total Views | 21367 |
Figure 2Post-course survey respondents by country of practice. (Color version of figure is available online.)
Figure 1Post-course survey respondents’ level of training. (Color version of figure is available online.)
Figure 3Post-course survey respondents’ evaluation of the lecture series benefit in their future practice. (Color version of figure is available online.)
Figure 4Attendees expectations of the lectures. (Color version of figure is available online.)
Figure 5Post-course survey respondents’ perception of virtual conferences before February 2020. (Color version of figure is available online.)
Figure 6Post-course survey respondents’ perception of virtual conferences after attending the online liver imaging series (OLIC). (Color version of figure is available online.)
Figure 7Post-course survey respondents’ answers to the question “Assuming widespread resumption of in-person conferences, will you continue to attend virtual conferences in the future?”. (Color version of figure is available online.)